The advancements in health care and available technologies have inadvertently led to an increase in the life expectancy of individuals. However, this has also led to a rise in the aging population worldwide. According to the United Nations, the aforementioned trend is one of the key transformations observed in the 21st century; it is expected to have an impact on all sections of the society. Aging is linked to a variety of diseases, including cardiovascular disorders, neurodegenerative disorders, oncological disorders and musculoskeletal disorders, which further puts heavy economic and psychological burden on the patients, their families and the society. As per the World Health Organization, in 2020, close to 1 billion people were estimated to be aged 65 or above, globally. In addition, the share of elderly population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging biology is still a largely unexplored field, in terms of the development of safe and effective novel pharmacotherapies. Anti-aging therapeutics, therefore, is an emerging field of medical science focused on reducing or reversing the underlying causes of aging through different mechanisms, in order to extend healthy lifespan of humans.
Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging. Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies. Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term.
The “Anti-aging Therapeutics Market - Distribution by Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others) and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World) - Industry Trends and Global Forecasts, 2022-2040” report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for anti-aging therapeutics, during the time period 2022-2040. The report also includes likely sales forecasts of anti-aging therapeutics that are in the mid to late stages of development. Additionally, it features market size projections for the overall anti-aging therapeutics market, wherein both the current and upcoming opportunity is segmented across [A] type of molecule (biologics and small molecules), [B] type of aging (cellular aging, immune aging, metabolic aging and others) and [C] key geographies (North America, Europe, Asia Pacific, and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.
Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging. Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies. Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term.
Scope of the Report
The “Anti-aging Therapeutics Market - Distribution by Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others) and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World) - Industry Trends and Global Forecasts, 2022-2040” report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain.
Amongst other elements, the report includes:
- A detailed assessment of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mammalian target of rapamycin (mTOR) inhibitor / modulator, adenosine monophosphate (AMP)-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter features analyses of anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates).
- A competitiveness analysis of anti-aging therapeutic developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule).
- An analysis of partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships), type of partner and regional distribution of collaborations.
- A detailed analysis of investments that have been made into companies which are developing proprietary anti-aging therapeutics, during period 2018-2022. The various types of funding instances reported in this domain include pre-seed financing, seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, crowdfunding, and donations.
- An in-depth analysis of the various patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, key focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed valuation analysis.
- A detailed review of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publisher, most popular journal, most popular affiliations and most popular funding institutes (in terms of number of articles published).
- A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors.
- Elaborate profiles of prominent players engaged in the development of anti-aging therapeutics, featuring a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for anti-aging therapeutics, during the time period 2022-2040. The report also includes likely sales forecasts of anti-aging therapeutics that are in the mid to late stages of development. Additionally, it features market size projections for the overall anti-aging therapeutics market, wherein both the current and upcoming opportunity is segmented across [A] type of molecule (biologics and small molecules), [B] type of aging (cellular aging, immune aging, metabolic aging and others) and [C] key geographies (North America, Europe, Asia Pacific, and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.
The report features detailed transcripts of interviews held with the following individuals:
- Peter Fedichev (Co-Founder and Chief Executive Officer, Gero.AI)
- James Clement (President, Betterhumans)
- Wee Kiat Tan (Chief Operating Officer, CytoMed Therapeutics)
- Rosa Argyropoulos (Senior Director of Global Corporate Communications, Cambrian Biopharma)
- Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist, Landmark Medical Centre)
Key Questions Answered
- Who are the leading players engaged in the development of anti-aging therapeutics?
- What types of partnership models are commonly adopted by industry stakeholders engaged in this industry?
- Who are the key investors in the anti-aging therapeutics domain?
- How is the intellectual property landscape in this field likely to evolve in the foreseen future?
- What is the evolving trend of publications focused on anti-aging therapeutics?
- What are the key value drivers that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
1. PREFACE
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY COMPETITIVENESS ANALYSIS
6. PARTNERSHIPS AND COLLABORATIONS
7. FUNDING AND INVESTMENTS
8. PATENT ANALYSIS
9. PUBLICATION ANALYSIS
10. PORTER’S FIVE FORCES ANALYSIS
11. COMPANY PROFILES
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13. EXECUTIVE INSIGHTS
List Of Figures
List Of Tables
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advancells
- AgelessRx
- AgeX Therapeutics
- Albert Einstein College of Medicine
- Albert Ludwig University of Freiburg
- Altos Labs
- Amorepacific
- Anhui Agricultural University
- ANOVA Institute for Regenerative Medicine
- Antoxerene (Subsidiary of Ichor Therapeutics)
- Astellas Pharma
- Baylor College of Medicine
- Beihua University
- Betterhumans
- BioAge Labs
- Biophytis
- Bioquark
- BioXcellerator
- Brigham and Women's Hospital
- Buck Institute for Research on Aging
- Cambrian Biopharma
- Carnegie Mellon University
- Case Western Reserve University School of Medicine
- Cedars-Sinai Medical Center
- cellvie
- Centaura
- Central South University
- Chia Nan University of Pharmacy and Science
- Chinese Academy of Medical Sciences
- Chongqing University of Education
- Cleara Biotech
- Cornell University
- Cosmax
- Covalent Bioscience
- CytoMed Therapeutics
- Dorian Therapeutics
- ETTA Biotechnology
- European Research Council (ERC)
- Florica Therapeutics
- Fountain Therapeutics
- FoxBio
- Georgia Institute of Technology
- Gero.ai
- Gerostate Alpha
- Gray Matter
- Grifols
- Gustave Roussy
- Hackensack Meridian Health
- Harvard T.H. Chan School of Public Health
- HCW Biologics
- Huazhong University of Science and Technology
- Inserm
- Insilico Medicine
- Intervene Immune
- Jilin University
- Johns Hopkins University
- Jumpstart Fertility (Subsidiary of Life Biosciences)
- Juvenescence
- Korea Research Institute of Bioscience and Biotechnology (KRIBB)
- Landmark Medical Centre (LMC)
- Life Biosciences
- Longevica
- Louisiana State University (LSU)
- Lunella Biotech
- LyGenesis
- Massachusetts General Hospital
- Mayo Clinic
- Medical University of Graz
- Ministry of Education, University and Research (MIUR)
- Montefiore Medical Center
- MyMD Pharmaceuticals
- Nanna Therapeutics (Acquired by Astellas Pharma)
- National Institute on Aging
- National Institutes of Health (NIH)
- National Natural Science Foundation of China
- Navitor Pharmaceuticals
- Neopharm
- NewLimit
- Office of Research Infrastructure Programs
- Northeastern University
- Northwestern University
- Nuritas
- Nurosene
- Oisin Biotechnologies
- Oklahoma Medical Research Foundation (OMRF)
- Okyanos Center for Regenerative Medicine
- Orthogen
- Peking University
- Perelman School of Medicine at the University of Pennsylvania
- Rejenevie Therapeutics
- Rejuvenate Bio
- Rejuveron Life Sciences
- Repair Biotechnologies
- resTORbio
- Sanford Burnham Prebys Medical Discovery Institute
- Selphagy Therapeutics (Subsidiary of Life Biosciences)
- SENISCA
- Senolytic Therapeutics (Subsidiary of Life Biosciences)
- Shanghai Bohui Biological Technology
- Shanghai Jiao Tong University
- Shift Bioscience
- Shimadzu Scientific Instruments (Subsidiary of Shimadzu)
- Shiseido
- Sloan Kettering Institute (SKI)
- South Florida Bone Marrow/Stem Cell Transplant Institute
- Spring Discovery
- Springs Rejuvenation
- Stanford University
- Stony Brook University
- Sun Yat-sen University
- Taisho Pharmaceutical
- TCI
- The Pennsylvania State University
- The Rockefeller University
- UT Health San Antonio
- The University of Texas McGovern Medical School
- TruDiagnostic
- Tufts University
- Turn Biotechnologies
- UNITY Biotechnology
- University of California
- University of California, Berkeley (UCB)
- University of California, San Francisco (UCSF)
- University of Colorado
- University of Massachusetts Medical School
- University of Minnesota
- University of North Carolina at Chapel Hill
- University of Southern California
- University of Texas Southwestern Medical Center
- University of Wisconsin-Madison
- Vanderbilt University
- Velabs Therapeutics
- Washington University
- Wellcome Trust
- Whitehead Institute for Biomedical Research
- Yale University
- Zhejiang Huitai Life Health Technology
Methodology
LOADING...
